Abstract
Context: Chronic myeloid leukemia (CML) is believed to occur following the clonal expansion of haematopoietic stem cells and is maintained by expanding clones which have acquired a BCR-ABL fusion gene. The properties of untreated CML stem/progenitor cells correlate with a subsequent response to chemotherapy. Evidence Acquisition: The fifty two significant articles discussing the stem cell in chronic myeloid leukemia from 1996 to 2012 were selected according to the authors’ experience. Results: Studies have shown that primitive CML cells are less responsive to Tyrosine Kinase Inhibitors (TKIs) and are a reservoir for the relapse of multi drug resistant (MDR). Conclusions: Following that, minimal residual disease (MRD) measurement aims to detect very small numbers of leukemic cells, below the detection limit of morphology and cytogenetics with molecular techniques for patients in clinical remission.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
